Identification and functional characterization of a new gene encoding the mouse terminal complement inhibitor CD59

被引:68
作者
Qian, YM
Qin, XB
Miwa, T
Sun, XJ
Halperin, JA
Song, WC
机构
[1] Univ Penn, Sch Med, Ctr Expt Therapeut, Philadelphia, PA 19104 USA
[2] Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA
[3] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA
[4] Harvard Univ, Sch Med, Boston, MA 02115 USA
关键词
D O I
10.4049/jimmunol.165.5.2528
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
CD59 is a 18- to 20-kDa, GPI-anchored membrane protein that functions as a key regulator of the terminal step of the complement activation cascade. It restricts binding of C9 to the C5b-8 complex, thereby preventing the formation of the membrane attack complex (C5b-9 of complement). A single human CD59 gene has been identified, and corresponding genetic homologues from rat, mouse, and pig have been characterized in previous studies. In this study, we report the discovery and functional characterization of a separate cd59 gene in the mouse (referred to as cd59b, the previously characterized mouse cd59 gene as cd59a). Mouse cd59b is 85% and 63% identical to cd59a at the nucleotide and amino acid level, respectively. In cDNA transfection experiments with Chinese hamster ovary cells, peptide-tagged cd59b was detected on the cell surface by flow cytometry and was shown to be susceptible to phosphatidylinositol-specific phospholipase C cleavage. Chinese hamster ovary cells expressing cd59b were significantly more resistant than control cells to human and mouse complement-mediated lysis. These results suggest that cd59b encodes a GPI-anchored protein that is functionally active as a membrane attack complex inhibitor. Northern blot analysis revealed that cd59b is expressed selectively in the mouse testis. In contrast, the major transcript of cd59a was shown to be expressed at high levels in the heart, kidney, liver, and lung, but only minimally in the testis. These results revealed the existence of two distinct cd59 genes in the mouse that are differentially regulated and that may have nonoverlapping physiological functions in vivo.
引用
收藏
页码:2528 / 2534
页数:7
相关论文
共 42 条
  • [1] Molecular basis for a link between complement and the vascular complications of diabetes
    Acosta, J
    Hettinga, J
    Flückiger, R
    Krumrei, N
    Goldfine, A
    Angarita, L
    Halperin, J
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (10) : 5450 - 5455
  • [2] TERMINAL COMPLEMENT PROTEINS C5B-9 RELEASE BASIC FIBROBLAST GROWTH-FACTOR AND PLATELET-DERIVED GROWTH-FACTOR FROM ENDOTHELIAL-CELLS
    BENZAQUEN, LR
    NICHOLSONWELLER, A
    HALPERIN, JA
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1994, 179 (03) : 985 - 992
  • [3] COLOCALIZATION OF THE HUMAN CD59 GENE TO 11P13 WITH THE MIC11 CELL-SURFACE ANTIGEN
    BICKMORE, WA
    LONGBOTTOM, D
    OGHENE, K
    FLETCHER, JM
    VANHEYNINGEN, V
    [J]. GENOMICS, 1993, 17 (01) : 129 - 135
  • [4] SEVERAL VASCULAR COMPLEMENT INHIBITORS ARE PRESENT ON HUMAN SPERM
    BOZAS, SE
    KIRSZBAUM, L
    SPARROW, RL
    WALKER, ID
    [J]. BIOLOGY OF REPRODUCTION, 1993, 48 (03) : 503 - 511
  • [5] GLYCOLIPID ANCHORING OF PLASMA-MEMBRANE PROTEINS
    CROSS, GAM
    [J]. ANNUAL REVIEW OF CELL BIOLOGY, 1990, 6 : 1 - 39
  • [6] CD59, AN LY-6-LIKE PROTEIN EXPRESSED IN HUMAN LYMPHOID-CELLS, REGULATES THE ACTION OF THE COMPLEMENT MEMBRANE ATTACK COMPLEX ON HOMOLOGOUS CELLS
    DAVIES, A
    SIMMONS, DL
    HALE, G
    HARRISON, RA
    TIGHE, H
    LACHMANN, PJ
    WALDMANN, H
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1989, 170 (03) : 637 - 654
  • [7] DCRUZ OJ, 1990, J IMMUNOL, V144, P3841
  • [8] CHARACTERIZATION OF THE DECAY-ACCELERATING FACTOR GENE PROMOTER REGION
    EWULONU, UK
    RAVI, L
    MEDOF, ME
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (11) : 4675 - 4679
  • [9] TERMINAL COMPLEMENT COMPLEX C5B-9 STIMULATES MITOGENESIS IN 3T3 CELLS
    HALPERIN, JA
    TARATUSKA, A
    NICHOLSONWELLER, A
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1993, 91 (05) : 1974 - 1978
  • [10] Hinchliffe SJ, 1998, J IMMUNOL, V160, P3924